Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
Wilson GJ, Rodriguez B, Li SS, Allen M, Frank I, Rudnicki E, Trahey M, Kalams S, Hannaman D, Clarke DK, Xu R, Egan M, Eldridge J, Pensiero M, Latham T, Ferrari G, Montefiori DC, Tomaras GD, De Rosa SC, Jacobson JM, Miner MD, Elizaga M; HIV Vaccine Trials Network 112 Protocol Team. Wilson GJ, et al. Among authors: latham t. Vaccine. 2023 Apr 17;41(16):2696-2706. doi: 10.1016/j.vaccine.2023.03.015. Epub 2023 Mar 17. Vaccine. 2023. PMID: 36935288 Free PMC article. Clinical Trial.
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team. Elizaga ML, et al. PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018. PLoS One. 2018. PMID: 30235286 Free PMC article. Clinical Trial.
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network; Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A. Fuchs JD, et al. Among authors: latham t. Open Forum Infect Dis. 2015 Jun 5;2(3):ofv082. doi: 10.1093/ofid/ofv082. eCollection 2015 Sep. Open Forum Infect Dis. 2015. PMID: 26199949 Free PMC article.
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi CS, Luckay A, Witko SE, Hermida L, Higgins T, Tremblay M, Sciotto-Brown S, Chen T, Egan MA, Rusnak JM, Ward LA, Eldridge JH. Clarke DK, et al. Among authors: latham te. Lancet Infect Dis. 2020 Apr;20(4):455-466. doi: 10.1016/S1473-3099(19)30614-0. Epub 2020 Jan 14. Lancet Infect Dis. 2020. PMID: 31952923 Clinical Trial.
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH. Matassov D, et al. Among authors: latham t. J Virol. 2018 Jan 17;92(3):e01190-17. doi: 10.1128/JVI.01190-17. Print 2018 Feb 1. J Virol. 2018. PMID: 29142131 Free PMC article.
Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM, Leal G, Hamm S, Eldridge JH, Tesh RB, Clarke DK, Weaver SC. Nasar F, et al. Among authors: latham t. J Virol. 2017 Mar 29;91(8):e01729-16. doi: 10.1128/JVI.01729-16. Print 2017 Apr 15. J Virol. 2017. PMID: 28148802 Free PMC article.
Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.
Cross RW, Xu R, Matassov D, Hamm S, Latham TE, Gerardi CS, Nowak RM, Geisbert JB, Ota-Setlik A, Agans KN, Luckay A, Witko SE, Soukieh L, Deer DJ, Mire CE, Feldmann H, Happi C, Fenton KA, Eldridge JH, Geisbert TW. Cross RW, et al. J Clin Invest. 2020 Jan 2;130(1):539-551. doi: 10.1172/JCI131958. J Clin Invest. 2020. PMID: 31820871 Free PMC article.
Immune correlates of postexposure vaccine protection against Marburg virus.
Woolsey C, Jankeel A, Matassov D, Geisbert JB, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Latham TE, Gerardi CS, Mire CE, Eldridge JH, Messaoudi I, Geisbert TW. Woolsey C, et al. Sci Rep. 2020 Feb 20;10(1):3071. doi: 10.1038/s41598-020-59976-3. Sci Rep. 2020. PMID: 32080323 Free PMC article.
471 results